Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Dermatology | Family Medicine | Internal Medicine | Allergy | Nursing | Pharmacy | Rheumatology | Anesthesiology & Pain | Conference News

Back to Journal Articles

ACR: Vitamin D Beneficial in Systemic Lupus Erythematosus

Last Updated: November 07, 2011.

 

And, interferon-α-kinoid immunization is safe, shows promise for SLE

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
For patients with systemic lupus erythematosus (SLE), vitamin D supplementation is beneficial and modulates T regulatory cells; and immunization with interferon-α-kinoid is safe and shows positive results for patients with SLE, according to two studies being presented at the annual scientific meeting of the American College of Rheumatology, held from Nov. 5 to 9 in Chicago.

MONDAY, Nov. 7 (HealthDay News) -- For patients with systemic lupus erythematosus (SLE), vitamin D supplementation is beneficial and modulates T regulatory cells (Tregs); and immunization with interferon-α-kinoid (IFNα-K) is safe and shows positive results for patients with SLE, according to two studies being presented at the annual scientific meeting of the American College of Rheumatology, held from Nov. 5 to 9 in Chicago.

Benjamin Terrier, M.D., from the Pitié-Salpêtrière Hospital in Paris, and colleagues assessed the tolerance, immunologic, and clinical effects of vitamin D supplementation in SLE for 20 patients with hypovitaminosis D. Patients were assessed at day zero, at month two, and at month six. Supplementation was safe with no hypercalcemia or lithiasis. Supplementation increased the percentage of both naive and active Tregs. There was also an increase in expression of molecules associated with Treg suppression.

Frédéric A. Houssiau, M.D., Ph.D., from the Université catholique de Louvain in Belgium and colleagues assessed the safety and immunogenicity of 30, 60, 120, or 240 mg of intramuscular IFNα-K in 28 patients with mild and moderate SLE. The safety profile was favorable with few minor and transient local and systemic reactions noted. Lupus flares were seen in one patient in the treatment group who stopped glucocorticoid therapy after the first dose of IFNα-K, and one patient in the placebo group. All immunized patients had a dose-related anti-IFNα antibody response, with a peak after the last dose and decrease thereafter.

"This is the first study to show positive immune and pharmacodynamic results with active immunotherapy against interferon-α in the treatment of systemic lupus erythematosus," Houssiau and colleagues write.

Several of the study authors from the Houssiau study disclosed financial ties to Neovacs.

Press Release - Terrier
Press Release - Houssiau
More Information

Copyright © 2011 HealthDay. All rights reserved.


Previous: Causal Link Suggested Between Acetaminophen Use, Asthma Next: Gender Difference in Failure Patterns for Hip Resurfacing

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.